Clinical trial · Interventional
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma
NCT00318110CI-TRIAL-00023228terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Unable to meet subject enrollment goal.
Summary
Brief summary (as posted)
The purpose of this study is to find out what effects (good and bad) a stem cell transplant from an unrelated donor will have for patients with kidney cancer that has spread to other parts of the body (metastasized).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NST using MUD for metastatic renal cell carcinoma | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MUD treatment
- description
- NST using MUD for metastatic renal cell carcinoma
- interventionNames
- Procedure: NST using MUD for metastatic renal cell carcinoma
Primary outcomes (1)
- measure
- Determine the best rate of tumor response of complete response (CR) + complete unconfirmed response (CRU) + partial response (PR) within 6 months after matched unrelated donor (MUD) nonmyeloablative stem cell transplantation (NST)
- timeFrame
- 6 months
Secondary outcomes (6)
- measure
- Overall survival after MUD NST
- timeFrame
- Two years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of metastatic (stage IV) renal cell carcinoma (RCC) predominately clear cell type * Prior nephrectomy * Available HLA-matched (8/8, 7/8) unrelated donor * At least one prior immunotherapy; or immunotherapy + chemotherapy; or targeted therapy, for metastatic RCC. * Adequate organ function Exclusion Criteria: * Prior allogeneic stem cell transplantation * RCC with histology other than clear cell type * History or presence of brain metastasis
References
Publications (0)
Data not yet available
No reference posted for this study.